According to Mucosis, the loan will be redeemed only if the FluGEM clinical development program is concluded successfully.
Mucosis develops vaccines on the basis of its Mimopath technology, which is based on Lactococcus lactis, a safe bacterium commonly used in the food industry.
Mucosis has developed an easy technique to formulate the L lactis bacteria into non-living particles that can be loaded with antigens from viral, bacterial, or parasitic origin.
The antigen-covered particles form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.
Govert Schouten, CEO of Mucosis, said: “We are really pleased with the government’s financial support. This non-dilutive funding underlines the progress we have made so far and, even more importantly, strengthens our financial capabilities going forward. It will enable us to generate proof of efficacy with FluGEM in man”